INVESTMENT HIGHLIGHTS Portfolio with exceptional potential • Six promising vaccine candidates • AmVac AG Founded August 2005 Headquarters Zug, Switzerland Legal form Joint stock company under Swiss law (privately held) Share capital CHF 689.635,67 • Total funding • Strong Team and Renowned Advisors Straightforward development plans with Melinda-Kinga Karpati Foundress AmVac AG, entrepreneur; longterm advanced milestones to be reached in CEO experience in start-up management and corporate development (medtech, biotech and IT industry) the near future • • Marie-Christine Kopkow Attorney at Law, multiyear experience in commercial Chairman of the Board and Corporate Law and founding partner of a law Dr. George Kavkasidze Medical doctor, with academic degree of PhD; Head of Marketing and almost 20 years’ experience in biopharmaceutical Business Development Merck-Serono • Dr. Marian Wiegand Vaccine expert with many years’ experience as Head of R&D scientist for Crucell and the Max Planck Institute of Biochemistry Ferenc Zimonyi • ship programs for mass-vaccination Prof. Dr. Reinhard Glück International vaccine expert, president of Swiss Biotech Association Prof. Dr. Carlos A. Guzmán • Head Vaccinology, Helmholtz Centre for Infectious Diseases, Braunschweig/Germany strategic investors Prof. Dr. Wolfgang J. Head Research Molecular Virology, Max Planck Neubert Institute of Biochemistry, Martinsried/Germany Dr. med. Ladislav Prikler Direction Uroviva, Centre of Urology in Bulach and Clinic Hirslanden, Switzerland BUSINESS STRATEGY • Exploit • Drive • Build • Move TECHNOLOGY PLATFORMS 1.) Gynevac platform: Development of 2.) Sendai platform: New generation of therapeutic vaccines against the most prophylactic and therapeutic vaccines frequent urogenital diseases 3.) MALP2 platform: New generation reduced cost of goods PIPELINE PRODUCT AMV602 (Sendai Platform) INDICATION STATUS Gynecological infections, mainly bacterial vaginosis (BV) and trichomonads Phase III Other complications related to BV: preterm birth/HPV/HIV/ etc. Preparation of Phase III CP/BPH Preparation of Phase III Respiratory syncytial virus (RSV) Preparation of Phase I Preclinical Preclinical Preclinical TARGET MARKETS 2.) Sendai-Platform A) Benign prostate hyperplasia (BPH) B) Bacterial vaginosis (BV) C) Infections caused by respiratory Global market volume around USD 4 Global market for BV-treatment around syncytial virus (RSV) billion BPH affects ~50 million men aged USD 450 million, estimation for BV- Target over 50, and more than 33 million of prevention over USD 1 billion vaccination in seven major markets (e.g. these men suffer from moderate to severe population for preventive US, Japan, EU) about 206 million people. disease. Recent Milestones • Gynevac-Platform: Decoding of Immuno-timulating “Mode of Action” • Strategic partnership with Medinserv for secondary packaging, marketing and distribution of AmVac’s Gynevac vaccine in the Caucasus, Middle Asia and CIS regions • Establishment of a dedicated production facility and GMP-compliant manufacturing process for Gynevac in collaboration with Vakcina Kft. • Positive preclinical data supporting the potential of AmVac’s Sendai-based vaccine candidate for the prevention of infections caused by respiratory syncytial virus (RSV) •